Background: Published data regarding associations between the P275A polymorphism in the macrophagescavenger receptor 1 (MSR1) gene and prostate cancer (PCa) risk are inconclusive. The aim of this study wasto comprehensively evaluate the genetic risk of P275A polymorphism in MSR1 gene for PCa. Materials and
Methods: A systematic literature search was carried out in Pubmed, Medline (Ovid), Embase, CBM, CNKI,Weipu, and Wanfang databases, covering all available publications (last search was performed on Apr 27, 2015).Statistical analysis was performed using Revman 5.2 and STATA 10.1 software.
Results: A total of 5,017 casesand 4,869 controls in 12 case-control studies were included in this meta-analysis. When all groups were pooled,there was no evidence that the P275A polymorphism had a significant association with PCa under dominant(OR=0.93, 95%CI=0.81-1.06, and p=0.28), co-dominant (homogeneous OR=0.97, 95%CI=0.56-1.68, and p=0.92;heterogeneous OR=0.93, 95%CI=0.74-1.15, and p=0.49), recessive (OR=1.10, 95%CI=0.65-1.87, and p=0.73),over-dominant (OR=0.93, 95%CI=0.75-1.15, and p=0.50), and allelic (OR=0.95, 95%CI=0.77-1.16, and p=0.61)genetic models. For stratified analyses by ethnicity and study design, no significant associations were found in thewhite race, the yellow race, the black race and mixed ethnicity, and the population-based case-control (PCC) andhospital-based case-control (HCC) studies under all genetic models.
Conclusions: Based on our meta-analysis,the P275A polymorphism in the MSR1 gene is unlikely to be a risk factor for PCa.